Role of i.v. allopurinol and rasburicase in tumor lysis syndrome

2003 ◽  
Vol 60 (21) ◽  
pp. 2223-2224
Keyword(s):  
Tumor Lysis Syndrome ◽  
Tumor Lysis

scholarly journals Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist

2020 ◽  
Vol 8 ◽  
pp. 232470962094470 ◽  
Author(s):  
Vishal Patel ◽  
Robert Case
Keyword(s):  
Uric Acid ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Tumor Lysis Syndrome ◽  
General Internist ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Mantle Cell ◽  
Spontaneous Tumor Lysis Syndrome

Spontaneous tumor lysis syndrome (SPTLS) is a rare phenomenon that can manifest in rapidly proliferating hematological malignancies and solid tumors prior to initiating cytotoxic therapy. We encountered a patient who originally presented with diffuse lymphadenopathy, abdominal distention, and dyspnea, who had laboratory abnormalities suggestive of SPTLS. His peripheral flow cytometry and lymph node biopsy revealed blastoid-variant mantle cell lymphoma. Prior to initiating chemotherapy, acute kidney injury (AKI) and uric acid had improved with intravenous fluids and the initiation of allopurinol. However, after beginning chemotherapy, the patient developed a second AKI concerning for tumor lysis syndrome (TLS). He went on to have renal recovery and did not require renal replacement therapy. With the exception of case reports, there is limited evidence to guide general medicine clinicians who encounter cases of SPTLS. Expert-based guidelines are available to guide use of rasburicase, an uricase enzyme, before initiation of chemotherapy for certain malignancies when risk for TLS is considered high. Despite these guidelines, the role of rasburicase in preventing AKI remains controversial after inconclusive results in a meta-analysis. The causative relationship between uric acid and AKI in TLS is based on a mechanism of tubular obstruction. There are also mechanisms by which uric acid may cause AKI without tubular obstruction related to acute hyperuricemic nephropathy. Further characterization of the role of uric acid in causing AKI in patients without tubular obstruction may identify new mechanisms of injury and offer insight into new treatment strategies.

Role of i.v. allopurinol and rasburicase in tumor lysis syndrome

2003 ◽  
Vol 60 (21) ◽  
pp. 2213-2222 ◽  
Author(s):  
Mark T. Holdsworth ◽  
Phuongthao Nguyen
Keyword(s):  
Tumor Lysis Syndrome ◽  
Tumor Lysis

scholarly journals Transient Hyperammonemic Encephalopathy in a Child with Relapsed Acute Lymphoblastic Leukemia and Severe Tumor Lysis Syndrome

2021 ◽  
Vol 11 (01) ◽  
pp. e208-e211
Author(s):  
Ilja Dubinski ◽  
Tobias Feuchtinger ◽  
Esther Maier ◽  
Moritz Tacke ◽  
Florian Hoffmann
Keyword(s):  
Clinical Presentation ◽  
Lymphoblastic Leukemia ◽  
Tumor Lysis Syndrome ◽  
Poor General Condition ◽  
Diagnostic Dilemma ◽  
Severe Condition ◽  
Tumor Lysis ◽  
Qualitative And Quantitative ◽  
Acute Neurological Deterioration

AbstractIdiopathic hyperammonemia (IHA) is a severe condition, which has been reported in intensive chemotherapy and bone marrow transplantation. This case elucidates the diagnostic dilemma in children undergoing initiation of chemotherapy and developing severe disorders of qualitative and quantitative consciousness in the presence of hyperammonemia (HA) and lactic acidosis. The role of mitoxantrone as a causative agent for IHA in children is elusive. Children undergoing chemotherapy are often in a poor general condition, and the clinical presentation of HA is heterogeneous. This case should be a reminder for clinicians to check for HA in children with tumor lysis syndrome and acute neurological deterioration.

Clarifying the Role of Rasburicase in Tumor Lysis Syndrome

2007 ◽  
Vol 27 (1) ◽  
pp. 111-121 ◽  
Author(s):  
Amy R Sood ◽  
Lisa D Burry ◽  
Doret K. F Cheng
Keyword(s):  
Tumor Lysis Syndrome ◽  
Tumor Lysis

Acute Tumor Lysis Syndrome during Oral Fludarabine Treatment for Chronic Lymphocytic Leukemia. Role of Treatment with Rasburicase

Onkologie ◽  
2008 ◽  
Vol 31 (4) ◽  
pp. 197-199 ◽  
Author(s):  
Jose Manuel Calvo-Villas ◽  
Basilio Martín Urcuyo ◽  
Adelaida Morales Umpierrez ◽  
Francisco Sicilia
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tumor Lysis Syndrome ◽  
Lymphocytic Leukemia ◽  
Tumor Lysis

scholarly journals Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase

2017 ◽  
Vol Volume 10 ◽  
pp. 597-605 ◽  
Author(s):  
Nael Alakel ◽  
Jan Moritz Middeke ◽  
Johannes Schetelig ◽  
Martin Bornhäuser
Keyword(s):  
Tumor Lysis Syndrome ◽  
Tumor Lysis ◽  
Prevention And Treatment

scholarly journals Role of Hypouricemic Agents in Tumor Lysis Syndrome: A Meta-Analysis

2021 ◽  
pp. 183-196
Author(s):  
Waleed Alshehri ◽  
Abdulrahman Aljohani ◽  
Reem Alhasani ◽  
Anood Alshammari ◽  
Jwael A. Alhamoud ◽  
...  
Keyword(s):  
Uric Acid ◽  
Side Effects ◽  
Meta Analysis ◽  
Tumor Lysis Syndrome ◽  
Development Rate ◽  
Tumor Lysis ◽  
Scientific Databases ◽  
Life Threatening ◽  
Adults And Children

Objective and background: Tumor lysis syndrome (TLS) is a life-threatening emergency and demands emergency care of effective outcome with minimal or no side effects. The Hypouricemic agents, including Rasburicase, Allopurinol and Febuxostate used for the management of TLS. This study was designed to evaluate the Role of Hypouricemic agents by analyzing TLS development rate, control of uric acid, and Creatinine levels. Methods: An extensive electronic data search was conducted by using all leading scientific databases. Twenty-six studies were selected to conduct this study, as per the inclusion criteria. Results: The Odd ratio of TLS development rate was 4.06, 1.24, and 1.49 by Rusbricase, Allopurinol & Febuxostate administration respectively. 95% confidence interval was reported by selected studies against TLS development rate, Uric acid, and Creatinine levels by administrating Rusbricase, Allopurinol & Febuxostate. Conclusion: All Hypouricemic agents, including Rasburicase, Allopurinol and Febuxostate, are effective to manage Tumor lysis Syndrome. However, a suitable and most effective intervention dose needs to identify with better efficacy and minimal side effects both in Adults and Children. 

Role of intravenous allopurinol in the management of acute tumor lysis syndrome

2001 ◽  
Vol 28 (2B) ◽  
pp. 13-18 ◽  
Author(s):  
James Feusner ◽  
Margo S. Farber
Keyword(s):  
Tumor Lysis Syndrome ◽  
Tumor Lysis
Sign in / Sign up

Export Citation Format

Share Document